News | April 30, 2023
Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
Specialty Chemicals grew 38% YoY for FY23
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Bridging the gap between histopathology and molecular pathology
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Subscribe To Our Newsletter & Stay Updated
